Microscopic drug particles target Hard-to-Treat abdominal cancers in early trial
NCT ID NCT05159050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new way to deliver chemotherapy directly into the abdomen for people with advanced cancers that have spread to the lining of the belly. The treatment uses tiny particles loaded with paclitaxel, a standard chemo drug, to better target tumors. Only 4 people participated before the study ended, and the main goals were to check safety and find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERITONEAL CARCINOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Lab-Grown tumor models predict the best therapy for each patient?
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
- Light-Activated therapy shows promise for tumor control without surgery
- Cancer-Fighting virus shows promise in Hard-to-Treat ovarian cancer